Compare DexCom, Inc. (DXCM) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Raymond James Financial, Inc. — how do they compare? DexCom, Inc. trades at $78.38 (market cap $28.06B), while Raymond James Financial, Inc. trades at $169.7 (market cap $33.19B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays a 1.27% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | RJF | |
|---|---|---|
Market Cap | $28.06B | $33.19B |
Sector | Health | Financials |
52-Week High | $89.53 | $176.43 |
52-Week Low | $54.84 | $140.89 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Raymond James Financial (RJF) trades at $167.43, up 0.27% today, with a bullish technical signal and consistent earnings beats. Revenue grew to $13.84B in 2025, though net income margin dipped slightly to 15.42%. The stock is supported by a consensus price target of $176.83 and a declared $0.54 dividend payable in July 2026.
The outlook remains positive with strong analyst support and record revenues, but rising expenses and a high RSI near 75 indicate potential near-term volatility. Long-term growth is supported by advisor expansion and strategic acquisitions, though cost management remains a key focus for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
